This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Caggiano, V. Articles by Fridman, M. Search for Related Content PubMed Articles by Caggiano, V. Articles by Fridman, M. Social Bookmarking                   What's this?

Chemotherapy-induced moderate to severe anemia in intermediate-grade non-Hodgkin’s lymphoma patients

Sutter Cancer Center, and Sutter Institute for Medical Research, Sacramento, California

Rima E. Tannous, PharmD, MS

Amgen, Inc., Thousand Oaks, California

Sanjay Gupta, PhD, MBA

Amgen, Inc., Thousand Oaks, California

Moshe Fridman, PhD

AMF Consulting, Inc., Los Angeles, California

This study investigated the incidence of anemia in chemotherapy-treated intermediate-grade non-Hodgkin’s lymphoma (IGNHL) patients. A historic case series design was used. The study data were obtained from 12 oncology practices that participated in the Oncology Practice Pattern Study (OPPS). The analysis focused on 353 IGNHL patients with normal baseline (prechemotherapy) hemoglobin (Hb) (12.0 g/dL). These patients were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone combination) therapy (at some point) from 1993 through 1999. Anemia was found to be prominent during chemotherapy. About 24% of the patients with a normal baseline Hb level dropped below 10.0 g/dL and 49% dropped to 10.0 -11.9 g/dL, at some point during chemotherapy. As anemia treatment data were unavailable, it is likely that some of these patients received therapy to boost their Hb levels, rendering our results conservative. A logistic regression model revealed that in patients with normal baseline Hb, age 60, female gender, lower baseline Hb level, and lymphoma histology classified as the Working Formulation (WF) E or H were significant predictors of a drop in Hb below 10.0 g/dL during chemotherapy. Chemo-therapy-induced anemia is frequently observed in lymphoma patients. It is possible to identify adverse baseline patient characteristics associated with higher risk of chemotherapy-induced anemia and carefully monitor such patients. Additional studies in community oncology practice are warranted to validate these findings and improve our understanding of the problems of anemia in chemotherapy treated non-Hodgkin’s lymphoma (NHL) patients.

Key Words: anemia • chemotherapy • CHOP • hemoglobin • intermediate-grade non-Hodgkin’s lymphoma (IGNHL)

Journal of Oncology Pharmacy Practice, Vol. 8, No. 2-3, 73-80 (2002)
DOI: 10.1191/1078155202jp091oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?